Sanofi's $1.4 Billion Kymab Investment Struggles as Asthma Treatment Faces Challenges in Phase II Trials

Sanofi’s $1.4 Billion Kymab Investment Struggles as Asthma Treatment Faces Challenges in Phase II Trials

Sanofi's $1.4 Billion Kymab Investment Struggles as Asthma Treatment Faces Challenges in Phase II Trials